Gilead Sciences, Inc.
(GILD)
Add Watchlist
67.72 USD -0.04
Closed: 17 May, 3:55 pm
Symbol GILD
Market Cap 84.3B
Price 67.72
Open 67.82
52-wk High 87.87
50 Day Avg 69.40
Earnings Announcement 2024-08-01
Website https://www.gilead.com
Name Gilead Sciences, Inc.
Shares Outstanding 1,245,850,000
Change % -0.2063%
Low 67.21
52-wk Low 64.33
200 Day Avg 75.54
Last Dividend 3.08
Exchange NASDAQ
Volume 3,571,215
Previous Close 67.86
High 67.82
EPS 0.36
PE 188.11
Avg Volume 7,023,758
CUSIP 375558103
Gilead Sciences, Inc. Outlook
Description Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Currency USD
ISIN US3755581036
Industry Drug Manufacturers - General
Changes -0.14
CUSIP 375558103
Range 64.33 - 87.87
Beta 0.24
CIK 0000882095

Gilead Sciences, Inc. News

14-May-2024 10:09 AM

Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain. Four presentations will highlight real-world experience with Yescarta (axicabtagene ciloleucel), including manufacturing experience for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) i.

10-May-2024 10:01 AM

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

09-May-2024 4:05 PM

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.

09-May-2024 4:05 PM

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.

09-May-2024 9:00 AM

Will Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75?

Gilead Sciences stock (NASDAQ NASDAQ : GILD) trades at $65 per share, about 11% below the level seen in December 2021. GILD stock was trading at around $62 in early June 2022, just before the Fed started increasing rates, and is still close to that level, compared to a substantial 37% gain for the S&P 500 during this period.

07-May-2024 8:30 AM

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma. New Data Provide Detail on Trodelv.

06-May-2024 12:39 PM

Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back

If you really want to maximize your return potential, then acquiring stocks near 52-week lows could present a viable opportunity. Stated simply, it's a way to practice buying low and selling high.

06-May-2024 11:53 AM

MRNA, GILD: What to Watch in Biotech Stocks

Fiscal discipline is important going forward, notes Hartaj Singh on Moderna (MRNA). He discusses biotech stocks Moderna and Gilead Sciences (GILD).

01-May-2024 2:38 PM

Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar

Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.

30-Apr-2024 4:05 PM

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 14 at 11:20am Pacific Time RBCCM Global Healthcare Conference on Wednesday, May 15 at 10:30am Eastern Time Jefferies Global Healthcare Conference on Wednesday, June 5 at 11:00am Eastern Time Goldman Sachs Annual Global Healthcare Conference on Wednesday, June 12 at 1:20pm East.

29-Apr-2024 10:01 AM

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.